ClinicalTrials.gg
RecruitingNCT06256588JADEUpdated May 26, 2026

A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

A Phase 3 interventional study of Dostarlimab and Placebo in Neoplasms, Head and Neck, sponsored by GlaxoSmithKline. Recruiting at 277 sites in 31 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-26.

Primary conditionSquamous Cell Carcinoma of Head and NeckRegistry: Head and Neck NeoplasmsReclassifiedWhy we changed it
Registry
Head and Neck Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Squamous Cell Carcinoma of Head and Neck
Why
  1. The study's title name Squamous Cell Carcinoma of Head and Neck, a narrower term within Head and Neck Neoplasms.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
864
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States — 217 open to participants now, 347 under way, 28 of them phase 3. Squamous Cell Carcinoma of Head and Neck · United States.

Planned enrollment
12th of 993
864 · median 41
Started
2024
with 64 others
Phase 3
71 of 1,099
12 open now
Primary completion
2028-06
later than 241 of 346 live
Registered
947th of 1,099
by date

Among the 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States, this one is the 12th largest by planned enrollment of the 993 interventional ones that give a count, is one of 65 that started in 2024, is one of 71 in phase 3, reaches primary completion later than 241 of the 346 other live ones, and was the 947th registered.

Squamous Cell Carcinoma of Head and Neck

2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

217 of the 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States are open now. Recruiting first, the newest first:

212 more — sign in →

All 217 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States, or all of them as a file.
02

Study summary

The goal of this study is to assess the safety and effectiveness of Dostarlimab compared to Placebo in adult participants with Head and Neck Squamous Cell Carcinoma (HNSCC)

03

Conditions studied

  • Neoplasms, Head and Neck

Browse trials for

Keywords

  • JEMPERLI
  • Dostarlimab
  • Placebo
  • Chemoradiation
  • HNSCC
04

In context

Squamous Cell Carcinoma of Head and Neck Reclassified

2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

This study's planned enrollment of 864 is above the median of 48 across 1,653 interventional studies indexed under Squamous Cell Carcinoma of Head and Neck.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.

Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.

Compared within Squamous Cell Carcinoma of Head and Neck, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Head and Neck Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants are eligible to be included in the study only if all of the following criteria apply:

  • Has newly diagnosed unresected Locally Advanced (LA) confirmed HNSCC of the oral cavity, oropharynx, hypopharynx or larynx and completed cisplatin plus radiotherapy (termed "CRT" in this protocol) with curative intent and has no evidence of distant disease.
  • Has provided acceptable core or excisional obtained prior to CRT:

    • positive tumor status
    • If the primary tumor site is oropharyngeal carcinoma, the participant must have p16 immunohistochemistry (IHC) testing.
  • Has an (ECOG) performance status of 0 or 1
  • Has adequate organ function.

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  • Has received prior radiation therapy (RT), systemic therapy, targeted therapy, or surgery for management of head and neck cancer not considered part of CRT. Participants receiving induction chemotherapy are excluded. CRT combinations with components other than cisplatin and RT (e.g., experimental agents, including radiosensitizers/radioprotectants, cetuximab) are not eligible.
  • Has cancer outside of the oropharynx, larynx, hypopharynx or oral cavity, such as nasopharyngeal, sinus, other para-nasal, or other unknown primary head and neck cancer. Has more than one primary HNSCC tumor.
  • Has experienced any of the following with prior immunotherapy: any immune-related adverse event (irAE) of Grade ≥3, immune-related severe neurologic events of any grade (e.g., myasthenic syndrome/myasthenia gravis, encephalitis, Guillain-Barré Syndrome, or transverse myelitis), exfoliative dermatitis of any grade (Stevens-Johnson Syndrome, toxic epidermal necrolysis, or Drug Rash with Eosinophilia and Systemic Symptoms [DRESS] syndrome), or myocarditis of any grade. Non- laboratory abnormalities are not exclusionary.
  • Has undergone any major surgical procedure or experienced significant traumatic injury that has not resolved by the time of randomization.
  • Has any history of interstitial lung disease or pneumonitis (past or current).
  • Has cirrhosis of any stage or current unstable liver biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal/gastric varices, or persistent jaundice.
  • Has a history or current evidence of any medical condition, therapy, or laboratory abnormality that might confound the study results, interfere with their participation for the full duration of the study intervention, or indicate it is not in the best interest of the participant to participate, in the opinion of the investigator.
  • Is receiving any other anticancer or experimental therapy. No other experimental therapies (including but not limited to chemotherapy, radiation, hormonal treatment, antibody therapy, immunotherapy, gene therapy, vaccine therapy, or other experimental drugs) of any kind are permitted while the participant is receiving study intervention.
  • Previous treatment with , anti-PD-L1, or anti-PD-L2 agent or an agent directed to another stimulatory or coinhibitory T-cell receptor [e.g., Cytotoxic T-lymphocyte associated protein 4 (CTLA4), OX-40, CD137]
  • Is pregnant, breastfeeding, or expecting to conceive children within the projected duration of the study, starting with the Screening Visit through 120 days after the last dose of study intervention.
  • Has a history of severe allergic and/or anaphylactic reactions to chimeric, human or humanized antibodies, fusion proteins, or known allergies to dostarlimab or its .
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
864 participants (estimated)

Study arms

  • Experimental
    Arm A: Dostarlimab

    Drug: Dostarlimab

  • Placebo comparator
    Arm B: Placebo

    Drug: Placebo

Interventions

  • Dostarlimab will be administered as an intravenous (IV) infusion

  • DrugPlacebo

    Placebo will be administered as an IV infusion

07

What researchers measure

Primary outcomes

  1. Event-free Survival (EFS) Assessed by Blinded Independent Central Review (BICR)

    Event Free Survival (EFS) is defined as the time from the date of randomization to the date of an event, where an event is defined as locoregional progression or recurrence, or distant metastasis per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as per BICR; Salvage surgery at the primary tumor site; Neck dissection or surgery performed \>20 weeks after completion of Concomitant Chemoradiotherapy (CRT) when invasive cancer is present or Death from any cause.

    Time frame: Up to approximately 5 years

Secondary outcomes

  1. Overall Survival (OS)

    OS is defined as the time from date of randomization to the date of death by any cause.

    Time frame: Up to approximately 5 years

  2. Event-free Survival (EFS) assessed by investigator

    Event Free Survival (EFS) is defined as the time from the date of randomization to the date of an event as per primary endpoint, however with investigator assessment per RECIST 1.1

    Time frame: Up to approximately 5 years

  3. Number of Participants with treatment emergent adverse events (TEAEs), Immune-mediated TEAEs, and serious adverse events (SAEs) by severity

    Time frame: Up to approximately 5 years

  4. Number of Participants with TEAEs and SAEs leading to dose delays, withdrawals or death

    Time frame: Up to approximately 5 years

  5. Number of participants with clinically significant changes in laboratory, vital signs, and safety assessment parameters

    Time frame: Up to approximately 5 years

  6. Serum Concentration of Dostarlimab

    Time frame: Up to approximately 15 months

  7. Serum Concentration of Dostarlimab at End of Infusion (C-EoI)

    Time frame: Up to approximately 15 months

  8. Serum Predose trough concentration (Ctrough) of Dostarlimab

    Time frame: Up to approximately 15 months

  9. Number of Participants with Anti-Drug Antibodies against Dostarlimab

    Time frame: Up to approximately 15 months

08

Study locations

256 of 277 sites recruiting
  • GSK Investigational Site
    Jonesboro, Arkansas 72401, United States
    Recruiting
  • GSK Investigational Site
    Los Angeles, California 90095, United States
    Recruiting
  • GSK Investigational Site
    Solvang, California 93463, United States
    Recruiting
  • GSK Investigational Site
    Stockton, California 95204, United States
    Recruiting
  • GSK Investigational Site
    Torrance, California 90505, United States
    Recruiting
  • GSK Investigational Site
    Farmington, Connecticut 06030-1628, United States
    Recruiting
  • GSK Investigational Site
    New Haven, Connecticut 06520, United States
    Recruiting
  • GSK Investigational Site
    Washington D.C., District of Columbia 20010, United States
    Recruiting
  • GSK Investigational Site
    St. Petersburg, Florida 33709, United States
    Recruiting
  • GSK Investigational Site
    Tamarac, Florida 33321, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • GSK Investigational Site
    Atlanta, Georgia 30322, United States
    Recruiting
  • GSK Investigational Site
    Fort Wayne, Indiana 46804, United States
    Recruiting
  • GSK Investigational Site
    Iowa City, Iowa 52242, United States
    Recruiting
  • GSK Investigational Site
    Lexington, Kentucky 40536, United States
    Recruiting
  • GSK Investigational Site
    Columbia, Maryland 21044, United States
    Recruiting
  • GSK Investigational Site
    Worcester, Massachusetts 01655-0002, United States
    Recruiting
  • GSK Investigational Site
    St Louis, Missouri 63110, United States
    Recruiting
  • GSK Investigational Site
    Omaha, Nebraska 68114, United States
    Recruiting
  • GSK Investigational Site
    New York, New York 10032, United States
    Completed

    Not enrolling at this site — choose another above.

  • GSK Investigational Site
    The Bronx, New York 10468, United States
    Recruiting
  • GSK Investigational Site
    Canton, Ohio 44718, United States
    Recruiting
  • GSK Investigational Site
    Cincinnati, Ohio 45219, United States
    Completed

    Not enrolling at this site — choose another above.

  • GSK Investigational Site
    Tulsa, Oklahoma 74146, United States
    Recruiting
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19107, United States
    Recruiting
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15212, United States
    Recruiting
  • GSK Investigational Site
    Charleston, South Carolina 29425, United States
    Recruiting
  • GSK Investigational Site
    Greenville, South Carolina 29607, United States
    Completed

    Not enrolling at this site — choose another above.

  • GSK Investigational Site
    Chattanooga, Tennessee 37404, United States
    Recruiting
  • GSK Investigational Site
    Germantown, Tennessee 38138, United States
    Recruiting
  • GSK Investigational Site
    Nashville, Tennessee 37203, United States
    Recruiting
  • GSK Investigational Site
    Dallas, Texas 75246, United States
    Recruiting
  • GSK Investigational Site
    Fort Worth, Texas 76104, United States
    Recruiting
  • GSK Investigational Site
    San Antonio, Texas 78217, United States
    Recruiting
  • GSK Investigational Site
    Fredericksburg, Virginia 22408, United States
    Recruiting
  • GSK Investigational Site
    Wytheville, Virginia 24382, United States
    Recruiting
  • GSK Investigational Site
    Tacoma, Washington 98405, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • GSK Investigational Site
    Buenos Aires, 1023, Argentina
    Recruiting
  • GSK Investigational Site
    Buenos Aires, C1425, Argentina
    Recruiting
  • GSK Investigational Site
    Buenos Aires, C1437GZT, Argentina
    Recruiting
  • GSK Investigational Site
    Ciudad Autonoma de Buenos Aire, C1426, Argentina
    Recruiting
  • GSK Investigational Site
    Córdoba, 5000, Argentina
    Recruiting
  • GSK Investigational Site
    Florida, 1602, Argentina
    Recruiting
  • GSK Investigational Site
    Rosario, S2002, Argentina
    Recruiting
  • GSK Investigational Site
    San Juan, J5400, Argentina
    Recruiting
  • GSK Investigational Site
    San Miguel de Tucumán, T4000GTB, Argentina
    Recruiting
  • GSK Investigational Site
    Viedma, R8500ACE, Argentina
    Recruiting
  • GSK Investigational Site
    Blacktown, New South Wales 2148, Australia
    Recruiting
  • GSK Investigational Site
    Douglas, Queensland 4814, Australia
    Recruiting
  • GSK Investigational Site
    Herston, Queensland 4029, Australia
    Withdrawn

    Not enrolling at this site — choose another above.

  • GSK Investigational Site
    Ballarat, Victoria 3350, Australia
    Recruiting
  • GSK Investigational Site
    Geelong, Victoria 3220, Australia
    Recruiting
  • GSK Investigational Site
    Melbourne, Victoria 3004, Australia
    Completed

    Not enrolling at this site — choose another above.

  • GSK Investigational Site
    Brussels, 1200, Belgium
    Recruiting
  • GSK Investigational Site
    Charleroi, 6060, Belgium
    Recruiting
  • GSK Investigational Site
    Edegem, 2650, Belgium
    Recruiting
  • GSK Investigational Site
    Ghent, 9000, Belgium
    Recruiting
  • GSK Investigational Site
    Liège, 4000, Belgium
    Recruiting
  • GSK Investigational Site
    Yvoir, 5530, Belgium
    Recruiting
  • GSK Investigational Site
    Barretos, 14784-400, Brazil
    Recruiting
  • GSK Investigational Site
    Belo Horizonte, 30110-022, Brazil
    Recruiting
  • GSK Investigational Site
    Florianópolis, 88020-210, Brazil
    Recruiting
  • GSK Investigational Site
    Ijuí, 98700-000, Brazil
    Recruiting
  • GSK Investigational Site
    Jaú, 17210-120, Brazil
    Recruiting
  • GSK Investigational Site
    Joinville, 89201-260, Brazil
    Recruiting
  • GSK Investigational Site
    Natal, 59075-740, Brazil
    Recruiting
  • GSK Investigational Site
    Porto Alegre, 90610-000, Brazil
    Recruiting
  • GSK Investigational Site
    Salvador, 41253-190, Brazil
    Recruiting
  • GSK Investigational Site
    Salvador, 41950-640, Brazil
    Recruiting
  • GSK Investigational Site
    São José do Rio Preto, 15090-200, Brazil
    Recruiting
  • GSK Investigational Site
    São Paulo, 01246-000, Brazil
    Recruiting
  • GSK Investigational Site
    Vitória, 29043-260, Brazil
    Recruiting
  • GSK Investigational Site
    Greater Sudbury, Ontario P3E 5J1, Canada
    Recruiting
  • GSK Investigational Site
    Hamilton, Ontario L8V 5C2, Canada
    Recruiting
  • GSK Investigational Site
    Toronto, Ontario M5G 2M9, Canada
    Recruiting
  • GSK Investigational Site
    Montreal, Quebec H3T 1E2, Canada
    Completed

    Not enrolling at this site — choose another above.

  • GSK Investigational Site
    Chongqing, Chongqing Municipality 400030, China
    Recruiting
  • GSK Investigational Site
    Baoding, Hebei 071000, China
    Recruiting
  • GSK Investigational Site
    Nanyang, Henan 473005, China
    Recruiting
  • GSK Investigational Site
    Beijing, 100036, China
    Recruiting
  • GSK Investigational Site
    Changsha, 410013, China
    Recruiting
  • GSK Investigational Site
    Changzhou, 213032, China
    Recruiting
  • GSK Investigational Site
    Chengdu, 610000, China
    Recruiting
  • GSK Investigational Site
    Chengdu, 610041, China
    Recruiting
  • GSK Investigational Site
    Dongguan, 523059, China
    Recruiting
  • GSK Investigational Site
    Fuzhou, 350005, China
    Recruiting
  • GSK Investigational Site
    Fuzhou, 350014, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • GSK Investigational Site
    Guangzhou, 510120, China
    Recruiting
  • GSK Investigational Site
    Guangzhou, 510503, China
    Recruiting
  • GSK Investigational Site
    Hangzhou, 310003, China
    Recruiting
  • GSK Investigational Site
    Hangzhou, 310022, China
    Recruiting
  • GSK Investigational Site
    Hefei, 230001, China
    Recruiting
  • GSK Investigational Site
    Hengyang, 421000, China
    Recruiting
  • GSK Investigational Site
    Jinan, 250117, China
    Recruiting
  • GSK Investigational Site
    Kunming, 650106, China
    Recruiting
  • GSK Investigational Site
    Lanzhou, 730030, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • GSK Investigational Site
    Linyi, 276002, China
    Recruiting
  • GSK Investigational Site
    Nanchang, 330006, China
    Recruiting
  • GSK Investigational Site
    Nanchang, 330029, China
    Recruiting
  • GSK Investigational Site
    Nanning, 530021, China
    Recruiting
  • GSK Investigational Site
    Shanghai, 200032, China
    Recruiting

Showing the first 100 of 277 sites across 31 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Siu LL, Burtness B, Harrington K, Psyrri A, Saba NF, Tahara M, Carlson G, Dhar A, Grimshaw M, Hua L, Iadevaia R, Theti D, Vlahovic G, Machiels JP. JADE: phase 3 study of sequential dostarlimab post chemoradiotherapy in patients with locally advanced unresected HNSCC. Future Oncol. 2026 Feb;22(3):313-320. doi: 10.1080/14796694.2026.2619653. Epub 2026 Jan 30. PubMed 41612885 ↗

Individual participant data

Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Jun 2028, 51 months after the start.

Of 78 phase 3 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 117. This study's planned 51 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2024
First posted
Feb 13, 2024
StartActual
Mar 21, 2024
Primary completionEst.
Jun 30, 2028
CompletionEst.
Oct 26, 2029
Last update
May 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06256588
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Feb 13, 2024
Start date
Mar 21, 2024
Primary completion
Jun 30, 2028 (estimated)
Completion
Oct 26, 2029 (estimated)
Last update
May 26, 2026

Study contacts

US GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
877-379-3718
EU GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
+44 (0) 20 89904466

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dostarlimab

Start the discussion